1. Home
  2. EWTX vs WRBY Comparison

EWTX vs WRBY Comparison

Compare EWTX & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$28.57

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Warby Parker Inc.

WRBY

Warby Parker Inc.

HOLD

Current Price

$26.31

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EWTX
WRBY
Founded
2017
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EWTX
WRBY
Price
$28.57
$26.31
Analyst Decision
Buy
Buy
Analyst Count
7
13
Target Price
$34.71
$25.83
AVG Volume (30 Days)
1.1M
3.2M
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$850,580,000.00
Revenue This Year
N/A
$15.66
Revenue Next Year
N/A
$12.88
P/E Ratio
N/A
$10,511.07
Revenue Growth
N/A
14.55
52 Week Low
$10.60
$13.63
52 Week High
$30.48
$31.00

Technical Indicators

Market Signals
Indicator
EWTX
WRBY
Relative Strength Index (RSI) 56.47 51.14
Support Level $27.07 $25.25
Resistance Level $29.98 $26.98
Average True Range (ATR) 1.54 1.44
MACD -0.06 -0.28
Stochastic Oscillator 61.43 31.82

Price Performance

Historical Comparison
EWTX
WRBY

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Share on Social Networks: